Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Think Positive: Clovis Confident Of CHMP Okay For Rubraca

Feb 22 2018

• By Kevin Grogan

SC1802_Crossed Fingers_351834077_1200.jpg — Fingers crossed: Clovis expects good news from the CHMP in March • Source: Shutterstock

Related Content

Bumper Number Of 'Oral Explanations' Due At CHMP Meeting

Feb 21 2018

EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2<sup>nd</sup> Biosimilar Herceptin

Dec 15 2017

Tesaro Shakes Up EU PARP Market With Zejula Launches

Nov 22 2017

The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Jul 31 2017

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

Jan 15 2018

Related Companies

Clovis Oncology, Inc.

AstraZeneca PLC

Tesaro, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Additional Topics

Drug Review Approvals Companies Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window